Form 4: Vigil Neuroscience CEO Receives Stock Option Award
SEC Form 4 Filing
Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, Inc., was granted a stock option award for 485,000 shares on March 3, 2025.
Summary
- Ivana Magovcevic-Liebisch, the President and CEO of Vigil Neuroscience, Inc., received a stock option award.
- The award grants her the right to buy 485,000 shares of common stock at an exercise price of $2.19 per share.
- The transaction occurred on March 3, 2025.
- The options vest in 48 equal monthly installments, starting on April 3, 2025, and expire on March 3, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests. The sentiment is moderately positive as it indicates continued investment in the company's leadership.
Positives
- The stock option award aligns the CEO's interests with those of the shareholders, incentivizing her to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant (485,000 shares) and the vesting schedule (48 months) would need to be compared to similar companies of Vigil Neuroscience's size and stage to determine if it is in line with industry norms.
- Comparisons could be made to companies like Annexon Biosciences or Denali Therapeutics, considering their market capitalization and executive compensation structures.
Stakeholder Impact
- Shareholders may view the stock option award positively as it incentivizes the CEO to increase the company's value.
- Employees may see it as a sign of confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the stock option award transaction. |
| 04/03/2025 | First vesting date of the stock options. |
| 03/04/2025 | Date of the Form 4 filing. |
| 03/03/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.